Life Technologies, TrimGen Collaborate on Cancer Mutation Assays

NEW YORK (GenomeWeb News) – Life Technologies today announced that it will sell cancer mutation assays supplied by TrimGen to the research market.

Under the collaboration, assays for detecting KRAS and BRAF mutations will be developed and manufactured by TrimGen, which will supply the assays to Life Technologies. The assays will be sold under the Applied Biosystems brand and run on AB's capillary electrophoresis sequencing systems, including its new 3500 Series Genetic Analyzer.

The assays, which are intended for research use only, are expected to be launched in the first half of 2010.

Financial and further terms of the alliance were not disclosed.